Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region

Laboratory Investigation

Volumn 80, Issue 8, 2000, Pages 1291-1298

  Verkaik, Nicole S ^a   Van Steenbrugge, Gert J ^a   Van Weerden, Wytske M ^a   Bussemakers, Marion J ^b   Van Der Kwast, Theodorus H ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MESSENGER RNA;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN DEPLETION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

EID: 0033883379     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780137     Document Type: Article

References (31)

1. CD44 is the principal cell surface receptor for hyaluronate
2. Prostate specific antigen: Its clinical use and application in screening for prostate cancer
3. The relationship of DNA methylation to cancer
4. PSA screening for prostate cancer: The current controversy
5. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture
6. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
7. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated
8. DNA methylation, molecular genetic, and linkage studies in prostate cancer
9. Decreased levels of CD44 protein and mRNA in prostate carcinoma
10. How does DNA methylation repress transcription?
11. Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated
12. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker
13. Methylation of the CD44 metastasis suppressor gene in human prostate cancer
14. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
15. CD44: Structure, function, and association with the malignant process
16. Decreased expression of CD44 in metastatic prostate cancer
17. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy
18. Neuroendocrine differentiation in human prostatic tumor models
19. Cancer statistics
20. CD44 isoforms in metastatic cancer
21. CpG methylation, chromatin structure, and gene silencing: A three-way connection
22. Isolation of DNA from mammalian cells: Protocol I
23. DNA methylation in urological malignancies
24. Hyaluronate receptors: Key players in growth, differentiation, migration, and tumor progression
25. CD44 as a marker in human cancers
26. Splicing choice from ten variant exons establishes CD44 variability
27. Development and application of prostatic xenograft models for the study of human prostate cancer
28. Development of seven new human prostate tumor xenograft models and their histopathological characterization
29. Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation
30. Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study
31. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation, and carcinogenesis